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two aStable mixed hematopoietic chimerism has been consistently established in dogs who were mildly immuno-
suppressed by 200 cGy of total body irradiation (TBI) before undergoing dog leukocyte antigen (DLA)-iden-
tical bone marrow (BM) transplantation and who received a brief course of immunosuppression with
mycophenolate mofetil (28 days) and cyclosporine (35 days) after transplantation. However, when TBI
was reduced from 200 to 100 cGy, grafts were nearly uniformly rejected within 3-12 weeks. Here, we asked
whether stable engraftment could be accomplished after a suboptimal dose of 100 cGy TBI with host immu-
nosuppression enhanced by donor-derived mesenchymal stromal cells (MSCs) given after transplantation.
MSCs were cultured from BM cells and evaluated in vitro for antigen expression. They showed profound
immunosuppressive properties in mixed lymphocyte reactions (MLRs) in a cell dose–dependent manner
not restricted by DLA. MSC and lymphocyte contact was not required, indicating that immunosuppression
was mediated by soluble factors. Prostaglandin E2 was increased in culture supernatant when MSCs were
cocultured in MLRs. The addition of indomethacin restored lymphocyte proliferation in cultures containing
MSCs. MSCs expressed CD10, CD13, CD29, CD44, CD73/SH-3, CD90/Thy-1, and CD106/VCAM-1. For in
vivo studies, MSCs were injected on the day of BM grafting and on day 35, the day of discontinuation of post-
transplantation cyclosporine. MSCs derived from the respective BM donors failed to avert BM graft rejection
in 4 dogs who received DLA-identical grafts after nonmyeloablative conditioning with 100 cGy TBI in a time
course not significantly different from that of control dogs not given MSCs. Although the MSCs displayed in
vitro characteristics similar to those reported for MSCs from other species, their immunosuppressive
qualities failed to sustain stable BM engraftment in vivo in this canine model.
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466 Biol Blood Marrow Transplant 17:465-475, 2011W. S. Lee et al.was substituted for MMF in this model [3]. The most
likely role of pretransplantationTBIwas host immuno-
suppression, not creation of bone marrow (BM) space,
because dogs conditioned with 450 cGy irradiation to
the cervical, thoracic, and upper abdominal lymph
node chain, in lieu of 200 cGy TBI, engrafted [4].
Accordingly, other pretransplantation immunosup-
pression has been evaluated along with 100 cGy TBI
conditioning, and successful stable engraftment of
DLA-identical BM was achieved by blocking host T
cell costimulation with cytotoxic T lymphocyte antigen
4 immunoglobulin fusion protein (CTLA4-Ig) or anti-
body against CD154 along with donor lymphocytes
[5,6].Here, we used theDLA-identical BMgraftmodel
to determinewhether the immunomodulatory effects of
BM donor-derived mesenchymal stromal cells (MSCs)
could be substituted for T cell costimulatory blockade
in ensuring sustained hematopoietic engraftment.
MSCs have been described as multipotent nonhe-
matopoietic progenitor cells that can differentiate into
mature BM stromal cells, osteoblasts, adipocytes,
chondrocytes, fibrous tissue, neuroectoderm, and
visceral mesoderm [7-9]. They grow in culture as
adherent cells with spindle-shaped fibroblastic mor-
phology and typically do not express hematopoietic
markers on their surface, but do express adhesion mol-
ecules, growth factors and cytokines, and integrins
[10]. Cytokines and growth factors produced by
MSCs have been implicated in aspects of hematopoie-
sis. Pertinent to the present study, MSCs display
immunomodulatory effects. Human and mouse
MSCs suppress in vitro proliferation of lymphocytes
induced by alloantigens or mitogens [11-13], prolong
skin and cardiac allograft survival in mice [14], and
are thought to be useful for enhancing hematopoietic
engraftment [15] and treating graft-versus-host disease
(GVHD) in human patients [16,17]. The mechanisms
underlying these effects of MSCs have not been clearly
identified, although most studies have reported an
involvement of soluble factors [18].
Ex vivo expanded gene-marked MSCs have been
previously evaluated in dogs for their ability to localize
in the BM [19]. In the present study, we phenotypically
characterized canine MSCs and demonstrated their
ability to suppress mixed leukocyte reactions (MLRs).
Despite their profound in vitro immunosuppressive
activity, BM donor-derived MSCs failed to show in
vivo immunosuppressive properties in dogs, as demon-
strated by the dogs’ inability to sustain stable BM
engraftment after low-dose TBI exposure.MATERIALS AND METHODS
Laboratory Animals
The Institutional Animal Care and Use Commit-
tee at the Fred Hutchinson Cancer Research Center,which is fully accredited by the Association for Assess-
ment and Accreditation of Laboratory Animal Care,
approved this study. All dogs were enrolled in
a veterinary preventive medicine program as described
previously [1]. Cells from 10 DLA-mismatched and
unrelated dog pairs (20 dogs) were used for the MLR
studies. Four DLA-identical littermate pairs, aged
8-12 months (median, 10 months), were used for BM
transplantation. DLA identity was determined by
matching for highly polymorphic DLA class 1– and
class 2–associated microsatellite markers [20]. In
addition, the specific DLA-DRB1 allele identity was
confirmed by direct sequencing [21].BM–Derived Stromal Cell and Cell Lines
BM (25 mL) was obtained from the humeri of do-
nors by aspiration. This sample was hemolyzed with
sterile ammonium chloride lysing solution (155 mM
ammonium chloride, 10 mM sodium bicarbonate,
and 0.1mMEDTA) in a 37Cwater bath for 5minutes.
After centrifugation at 800 rpm for 5 minutes, the
resulting pellet was resuspended in 5 mL of Iscove’s
Modified Dulbecco’s Medium (IMDM) plus 10% fetal
bovine serum (FBS). BM red blood cell lyses have been
shown to be more efficient than Ficoll separation for
isolating MSCs [22]. BM cells were plated at a density
of 2  107 cells per 75-m2 culture flask (Costar,
Cambridge, MA) in 20 mL of IMDM containing
10% FBS and 1% penicillin/streptomycin (100 U/
mL). Extra cells were frozen in medium containing
10% DMSO. Nonadherent cells were removed after
72 hours of culture with a change of medium. Subse-
quently, half of the medium was changed twice
a week. After 2-3 weeks, cultured cells were detached
using 0.05% trypsin EDTA, washed by centrifugation,
and expanded to three 75-cm2 flasks. After reaching
confluency (2-3 weeks), cells were detached using
0.05% trypsin EDTA and tested for MSC function in
vitro. Frozen marrow cells were thawed and washed
in IMDM, and treated in the same manner as fresh
BM cells.Canine Fibroblasts
The canine fibroblast cell line (A-72) was pur-
chased fromAmericanTypeCulture Collection (Man-
assas, VA). In addition, canine primary skin fibroblasts
were obtained from skin punch biopsy, cut into several
small pieces, and washed in phosphate-buffered saline.
Fibroblasts were transferred into 6-well, 25-cm2 cul-
ture flasks (Costar) and cultured in RPMI medium
containing 20% FBS and 1% penicillin/streptomycin
(100 U/mL). Nonadherent cells were removed after
72 hours of culture by replacing the medium. Subse-
quently, these cells were cultured in the same manner
as MSCs.
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Monoclonal antibodies (mAbs) consisted of mouse
anti-canine CD34 (2E9, IgG1) [23], major histocom-
patibility (MHC) class II (H81.9F, IgG2a) [24],
CD45 (CA12.10C12, IgG1), CD3 (CA17.6F9,
IgG2b), and CD86 (CA24.3E4, IgG1). The latter 3
mAbs were a generous gift from Peter Moore, Univer-
sity of California Davis. Anti-human CD14 (TUK4,
IgG2a; Dako Cytomation, Glostrup, Denmark),
anti-CD58 (L306.4, IgG2a; Becton Dickinson, San
Jose, CA), anti-CD29 (MEM-101A, IgG1; Invitrogen,
Carlsbad, CA), anti-CD90 (DH2A, IgM; Accurate
Chemical, Westbury, NY), and anti-CD105 (555690,
IgG1; BD) were used because of their high cross-
reactivity with canine cells. Mouse anti-canine CD44
mAb (S5, IgG1) was kindly provided by Dr. Brenda
M. Sandmaier, Fred Hutchinson Cancer Research
Center [25]. The mAbs were either unconjugated or
conjugated to fluorescein isothiocyanate (FITC).
Isotype-matched control antibodies were used in
parallel as negative controls (Dako Cytomation).
Isotype-specific FITC-conjugated antibodies were
obtained from Southern Biotech (Birmingham, AL).
Flow cytometry was performed on a BD FACScan
using standard methods.Quantitative Reverse-Transcriptase
Polymerase Chain Reaction Analyses
For quantitative reverse-transcriptase polymerase
chain reaction (RT-PCR) analyses, RNAwas extracted
fromMSCs, primary skin fibroblasts, peripheral blood
mononuclear cells (PBMCs), and fresh BM cells using
TRIzol (Invitrogen) and chloroform. Isopropanol and
75% ethanol were used to precipitate and resuspend
the RNA. The RNA was dissolved in 100 mL of water.
cDNA was prepared using standard methods and
reagents (Invitrogen).Measurement of Cytokines in MSCs and
Fibroblast Culture Supernatant by
Enzyme-Linked Immunosorbent Assay
When culture flasks were 90% confluent, the cul-
ture medium was replaced, and the FBS reduced to
0.5%. Twenty-four hours later, the supernatant was
collected and concentrated 10-fold using Amicon
10K molecular weight cutoff filters (Millipore, Biller-
ica, MA). IMDM plus 0.5% FBS medium was used
as a negative control. Prostaglandin E2 (PGE2) levels
in the cell culture supernatants (not concentrated)
were measured by a competitive enzyme-linked immu-
nosorbent assay (ELISA) technique using a commer-
cially available ELISA kit (KGE004; R&D Systems,
Minneapolis, MN), according to the manufacturer’s
instructions. All other cytokines except PGE2 were
quantified using a sandwich-type assay.The following capture/detection antibodies recog-
nizing canine antigens were used: for tumor necrosis
factor (TNF)-a, MAB610/BAF210; for interleukin
(IL)-2, MAB602/BAF202; for stem cell factor (SCF),
MAB65/BAF255; for stromal cell–derived factor
1 (SDF1)-a, MAB350/BAF310; for transforming
growth factor (TGF)-b, MAB240/BAF240; for
vascular endothelial growth factor (VEGF), AF-293-
NA/BAF293; for IL-10, M-010/M-011-B; and for
interferon (IFN)-g, MAB781/BAF781. All reagents
were obtained from R&D Systems.MLR
Allogeneic MLRs were performed with lympho-
cytes from DLA-mismatched dogs in round-
bottomed 96-well plates in 200 mL of dog medium
consisting of 42% IMDM, 42%Waymouth’s medium,
10% heat-inactivated dog serum, 1% sodium pyruvate,
1%nonessential amino acids, 1%penicillin/streptomy-
cin, and 2% glutamine.MSCswere added at a stratified
dose (1  104 to 1  103 cells per well) with responder
and irradiated (2200 rad) stimulator lymphocytes from
each dog at a concentration of 1  105 cells per well.
InMLRs (with or withoutMSCs), cytokines, neutraliz-
ing antibodies, or biochemical antagonists were added
at the concentrations indicated. For MLRs cultured
with BM cells, BM was harvested from the humerus
and used at the same stratified dose as for MSCs after
hemolysis of the sample with ammonium chloride
lysing solution. Indomethacin was used to block
PGE2 synthesis at a concentration of 20 mM (Cayman
Chemical, Ann Arbor, MI). For MLRs containing
MSC-conditioned medium, the 7-day culture superna-
tants were collected from 90% confluent MSCs
established after 4weeks in culture. Lymphocyte prolif-
eration was measured on day 7 after an 18-hour pulse
with [3H]-thymidine (1.04 mCi/well; PerkinElmer,
Boston, MA). [3H]-thymidine incorporation was mea-
sured using a liquid scintillation counter (TopCount
NXT; PerkinElmer), expressed as cpm, representing
the mean of four separate replicates. Concanavalin A
(Con A; Sigma-Aldrich, St Louis, MO) was used as
a control to induce lymphocyte proliferation.Transwell Cultures
Transwell chambers with 0.4-mm pore membrane
(Millicell Cell Culture Insert, 12 mm; Millipore, Bed-
ford, MA) were used to coculture PBMCs with MSCs.
Responder lymphocytes (2  106cells/well) were
cultured with 2200 rad–irradiated stimulator lympho-
cytes (2  106cells/well) in a lower chamber. MSCs
(1 106 cells/well) were cultured in an inner transwell
chamber. After 6 days, the transwell chambers were re-
moved, and [3H]-thymidine was added at 10 mCi/well.
Twenty-four hours later, the sample was transferred to
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and the cells were cultured for an additional 18 hours.
Anti-CD3 and Anti-CD28 Antibody–Induced
Cell Stimulation
Round-bottomed96-well culture plateswere coated
with anti-CD3 (17.6F9; 5 mg/mL) (provided by Peter
Moore, University of California Davis) and anti-CD28
with agonistic activity (5B8; 10 mg/mL) (Graves et al.,
unpublished data) to induce cell stimulation. Responder
lymphocytes (1  105 cells/well) were cocultured with
20-Gy–irradiatedMSCs for 3 or 5 days. [3H]-thymidine
was added to each well (10 mCi/well) and cultured for
another 6 hours. [3H]-tymidine incorporation was
determined by a liquid scintillation counter.
HCTwith Added Cultured BM-Derived
Stromal Cells
BMfromeachof the intendedDLA-identical hema-
topoietic cell donors was harvested on days -35 and -28
from thehumeri (25mL) for culture as describedbefore.
On day 0, BM/MSC recipients were treated with 100
cGy TBI, provided at a rate of 7 cGy/min from a linear
accelerator (Clinac 6; Varian, Palo Alto, CA). Three
hours after TBI, MSCs were injected i.v. at concentra-
tions of 1.2-1.8  106 cells/kg. BM containing
1.19-6.11  108 total nucleated cells/kg of recipient
body weight (median, 4.14  108) was injected i.v. 3
hours later. Posttransplantation immunosuppression
consisted of MMF 10 mg/kg twice daily, injected s.c.
ondays 0-28, andCsA15mg/kg twice daily, givenorally
on days 21 to 35. On day 35, a second infusion of BM
donor-derived MSCs was given i.v. at concentrations
of 1.1-1.3  106 cells/kg.
Donor chimerism levels among nucleated PBSCs
were assessed weekly by fluorescent variable-number
tandem repeat polymerase chain reaction (VNTR-
PCR) assays [26]. Neutrophil recovery after the
postradiation nadir was defined as the first of 3 consec-
utive days with a neutrophil count .500 cells/mL.
Platelet recovery was defined as the first of 5 consecu-
tive days with an unsupported platelet count.20,000/
mL. Data from dogs in this study were compared with
those from a historical group of 11 dogs who were
given DLA-identical BM grafts after 100 cGy TBI
and received posttransplantation immunosuppression
with CsA and MMF or CsA and rapamycin without
MSC injections [1,3].RESULTS
Morphology and Surface Determinants of MSCs
and Fibroblasts
MSC derived from BM cells, immortalized canine
fibroblasts (A-72), and skin-derived primary caninefibroblasts all grew as spindle-like adherent cells
(Figure 1). Expression of key cell surface determinants
was assessed in part to phenotypically differentiate
MSC from the A-72 cell line or primary skin fibro-
blasts. MSCs, A-72 fibroblasts, and primary skin
fibroblasts all stained positively with anti-CD29,
anti-CD44 mAb, and anti-CD90, but not with
CD105 (endoglin) (Figure 2A). All 3 cell types were
negative for the hematopoietic cell surface antigens
CD3, CD14, CD34, and CD45 (data not shown).
RT-PCR analyses of cDNA prepared from MSCs and
the A-72 fibroblasts were performed to confirm the
presence or absence of antibody immunoreactivity and
to evaluate the expression of cell surface determinants
for which mAbs were not available. MSCs expressed
CD73, CD90, CD106, CD10, CD13, and CD29
(Figure 2B). A-72 fibroblasts expressed all of these
antigens except CD106. MSCs expressed CD10, but
BM cells and PBMCs did not (data not shown). All
RT-PCR expression levels were normalized to
glyceraldehyde-3-phosphate dehydrogenase (GAPD).
Cytokine Secretion for Canine MSCs
Human andmouseMSCs have been shown to pro-
duce several cytokines and growth factors (eg, TGF-b)
and biological mediators (eg, PGE2) in in vitro cul-
tures. To determine whether canine MSCs produce
these molecules, we measured the expression of SDF-
1, TGF-b, and VEGF in supernatants of MSCs and
A-72 fibroblast cells by ELISA. MSCs produced only
TGF-b (932 pg/mL, actual) and VEGF (11.8 ng/
mL), whereas fibroblasts secreted VEGF (10.8 ng/
mL), significantly less TGF-b (176 ng/mL) than
MSCs, and 10 ng/mL of SDF-1. TNF-a, IL-2, SCF,
IL-10, IFN-g, and PGE2 were not detected in either
MSC or fibroblast culture supernatants (data not
shown). Subsequent experiments demonstrated that
the levels of TGF-b detected in the MSC supernatants
were not sufficient to suppressMLRs (data not shown).
MSCs Suppress Lymphocyte Proliferation
Human and murine MSCs suppress lymphocyte
proliferation in an MHC-unrestricted manner [27].
Both canine MSCs and A-72 fibroblasts also sup-
pressed MLR established with PBMCs from 2
DLA-mismatched dogs in a dose-dependent fashion
(Figure 3A and B).
Skin fibroblasts from primary cultures suppressed
MLRs similar to the fibroblast cell line A-72 (data
not shown). Suppression was DLA-unrestricted; MSCs
from a third-party dog or as A-72 fibroblasts suppressed
MLRequally as well asMSCs isolated from the dog that
supplied the responder lymphocytes. Freshly isolated
BM cells failed to suppress MLRs (Figure 3C).
Previous studies have shown that human MSCs
suppress lymphocyte proliferation induced by anti-
Figure 1. Morphological features of marrow-derived MSCs, A-72 canine fibroblasts, and primary skin canine fibroblasts. At 2 weeks after marrow col-
lection, MSCs were cultured to 40% confluence (A) and 100% confluence (B). A-72 cells were cultured to 30% confluence (C) and 80% confluence (D).
Primary canine fibroblasts from skin biopsy specimens were cultured to 50% confluence (E) and 90% confluence (F). (Original magnification, 100.)
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whether stimulator cells are required for canine
MSC–mediated immunosuppression, PBMCs were
cultured with canine-specific anti-CD3 and anti-
CD28 mAb in the presence or absence of MSCs. As
shown in Figure 3D, MSC suppressed CD3/CD28-
induced cell proliferation in a dose-dependentmanner.Cell-to-Cell Contact Is Not Required for
MSC-Mediated Suppression
Supernatants collected from confluent cultures of
MSCs at concentrations as great as 25% of the total
volume of the MLR culture failed to suppress prolifer-
ation (data not shown). However, adding MSCs to the
inner chamber of a transwell culture system resulted in
MLR suppression as strong as that achieved by placing
an equivalent number of MSCs in direct contact with
PBMCs (Figure 4). This demonstrates that direct
cell-to-cell contact between MSCs and PBMCs is
not required for MSC-mediated suppression.PGE2 Plays a Key Role in the MSC-Mediated
Inhibition of MLR
Results of the transwell assays suggest that soluble
factor(s) induced after interaction between MSCs andlymphocytes are responsible for the immunosuppres-
sive effect of MSCs. Human MSCs secrete PGE2,
which is thought to play an important role in MSC-
mediated immunomodulation [28]. Based on this, we
measured PGE2 in 4-day supernatants collected
from MLR cultures containing MSCs. Supernatants
collected from plates containing MSCs cultured alone
for 4 days were used as a control. As shown in
Figure 5A, PGE2 production was dramatically in-
creased in cocultures of MSCs plus responder and
stimulator PBMCs relative to either cell population
cultured alone.
To confirm that PGE2 plays a major role in
the MSC-mediated inhibition of MLRs, we added
indomethacin (20 mM), an inhibitor of PGE2 produc-
tion, to MLRs containing MSCs. Lymphocyte prolif-
eration in the presence of indomethacin was restored
in MLRs containing MSCs at 1 103, 5 103 and, to
a lesser (50%) extent, 1  104 cells per well
(Figure 5B).
Effect of MSCs on HCTafter 100 cGy TBI
The potential in vivo immunosuppressive effects
of MSCs were tested in 4 dogs that underwent
DLA-identical HCT after conditioning with 100
cGy TBI followed by postgrafting MMF and CSP.
Figure 2. Expression of cell surface determinants on canine MSCs and fibroblasts. (A) Cells were released from tissue culture plates using phosphate
buffered saline/EDTA and treated with anti-CD29, anti-CD44, anti-CD90, or anti-CD105, washed by centrifugation, and analyzed by flow cytometry.
Filled regions indicate antibody binding, and fine lines indicate binding by isotype controls. (B) Quantitative RT-PCR analysis was used to confirm the
presence or absence of expression of cell surface proteins shown in (A) and to characterize the expression of proteins for which mAbs were not avail-
able. mRNA was obtained from cultured MSCs or canine fibroblast cell line A-72. Arrowheads indicate amplified DNA of the expected size. Molecular
sizes were as follows: CD73, 182 bp; CD90/Thy-1, 218 bp; CD105/endoglin, 237 bp; CD106/VCAM-1, 237 bp; CD10, 300 bp; CD13, 272 bp; and CD29,
281 bp. GAPD was used as a standard. The ladder is shown in 100-bp increments to 500 bp.
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of HCT and after completion of CsA administration
(day 35). The suppressive activity of each lot of
MSCs was tested in vitro at the time of infusion and
found to be 31.7%-91.5% of that of controls (median,
71%) (Table 1). The kinetics of neutrophil and platelet
count nadirs and recoveries in the 4 dogs that under-
went HCT did not differ from those of 11 historical
controls (data not shown). Donor neutrophil and
lymphocyte chimerism results are shown in Figure 6.
Initial donor cell engraftment was documented in all
dogs, but all recipients eventually rejected their grafts
after 7-11 weeks (median, 8 weeks), similar to the 11
control dogs who received the same treatment but
without MSCs (Table 1). All dogs survived with autol-
ogous hematopoietic recovery. Administering MSCs
after HCT failed to affect the duration of engraftment
in dogs conditioned with an otherwise suboptimal dose
of 1 Gy TBI. With 90% confidence, the addition of
MSCs did not result in a usefully high engraftment
rate (50%).DISCUSSION
Numerous studies have indicated that BM-derived
murine or human MSCs have immunosuppressive ac-
tivity [13,27-31]. These characteristics have prompted
clinical studies evaluating MSCs for the enhancement
of hematopoietic engraftment [15,32] and the control
of GVHD after HCT [33]. The latter report on the
cure of steroid-refractory GVHD through infusion
of unrelated MSCs sparked widespread interest in
the clinical use of these cells. Subsequent reports
have been inconclusive as to the efficacy of these cells
in treating patients with GVHD and generally not in-
formative as to the mechanisms involved. Because
studies in dogs have been instrumental in the develop-
ment and understanding of clinically relevant HCT
regimens, we evaluated the immunosuppressive prop-
erties of MSCs in a dog model.
Our previous experience with MSCs in dogs was
limited to an attempt to identify the localization of ex
vivo expanded green fluorescent protein–transduced
Figure 3. Inhibition of MLR by canine MSCs and A-72 fibroblasts. (A and B) Marrow-derived MSCs (A) or A-72 cells (B) were added to wells containing
DLA-nonidentical responder and irradiated stimulator lymphocytes in a 7-day MLR. Data are presented as total counts per minute of 3H-thymidine
uptake. (C) Cultured MSCs from the dog supplying responder lymphocytes, cultured caMSCs from an unrelated mismatched dog, or canine fibroblasts
A-72, added at (104 cells/well) in the MLR did not differ significantly in their suppressive activity, whereas fresh bone marrow cells (caBM) at the same
concentration failed to suppress the MLR. (D) MSCs, in dilutions starting at 1 104 cells per well, suppressed lymphocyte proliferation in a 5-day culture
assay of PBMCs of a single dog stimulated with anti-canine CD3 and anti-canine CD8 antibodies.
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[19]. In that study, localization ofMSCswas inferredby
PCR detection of transgene sequences. Anecdotally,
we described bilateral diffuse pulmonary ectopic ossifi-
cation including myeloid BM after a DLA-matchedFigure 4. MSCs in transwell cultures suppress MLR. MSCs were placed
in transwell culture chambers at 1 106 cells per well, and PBMCs from
DLA-nonidentical dogs were placed in the outer chamber at 2  106
cells per well. After 6 days of culture, PBMCs were transferred to 96-
well format with 3H-thymidine for 18 hours. Suppression of lymphocyte
proliferation was compared in PBMCs incubated without caMSCs or cul-
tured in direct contact with caMSCs.BM graft, presumably resulting from the presence of
MSCs in the graft [34]. Another study (Mielcarek
et al., unpublished) investigated the in vivo distribution
of 111indium-labeled MSCs in dogs. Immediately after
infusion, MSCs were found in the lung, and within 24
hours, labeled cells were detected in liver and spleen
and, to a lesser extent, in BM and gut. Residual labeling
in liver and spleen could be detected for as long as
9 days.
The goal of the present study was to produce and
characterize canine MSCs relative to what has been
described for mouse and human MSCs. We success-
fully cultured MSCs from BM and found them to be
morphologically similar to human and mouse MSCs
[10,35]. The MSCs exhibited characteristics of
spindle-shaped fibroblastic cells, adherence to plastic
surfaces, and antiproliferative activity, similar to the
fibroblast cell line A-72 and skin-derived primary
canine fibroblasts. Human MSCs and fibroblasts also
have morphological similarities and the ability to
suppress MLRs [36].
MSCs have been reported to express various surface
markers, includingCD13,CD29,CD44,CD73,CD90,
Figure 5. Production of PGE2 by coculture of MSCs and PBMCs. (A)
PGE2 levels were measured by ELISA from 4-day culture supernatants
from MSCs, responder and stimulator PBMCs (Res1 Stim), and PBMCs
containing caMSC. (B) Indomethacin, a prostaglandin inhibitor (PGI) (20
mM, grey bars), or medium alone (open bars) was added to a 7-day MLR
containing dilutions of MSCs. Data are presented as percent inhibition
relative to MLR containing no MSCs.
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specific marker for MSCs has been identified [39].
Canine MSCs shared cell surface expression profilesTable 1. DurationOf DonorChimerism in DogsGivenMarrowGraf
or Rapamycin/CsA without MSCs (No MSC) or with 2 Injections of
MSCs, 106 Cells/kg Inhibition Index of M
Dog
Nucleated
Marrow Cells,
108 Cells/kg Day 0 Day 35 Day 0
MSC
G912 6.1 1.2 1.2 89.3
H039 1.2 1.5 1.3 44.5
H105 4.5 1.8 1.1 71.1
H182 3.8 1.3 1.1 69.2
No MSC [1]
E165 4.0 – – –
E166 4.0 – – –
E202 4.1 – – –
E204 4.0 – – –
E227 4.0 – – –
E228 4.0 – – –
No MSC [3]
G092 3.61 – – –
G111 6.27 – – –
G151 3.69 – – –
G156 3.8 – – –
G167 4.18 – – –
TBI indicates total body irradiation; MMF, mycophenolate mofetil; CsA, cyclos
percentage of control proliferation in MLR wells containing 104 MSCs/well.with human MSCs except for CD105, as determined
both by antibody staining and PCR methods. Antigen
expression by canine fibroblasts differed from MSCs
with respect to CD10, CD29, CD73, and CD106.
Of interest is the dose-dependent immunosuppres-
sive effect of canine MSCs against lymphocytes, which
was not restricted by DLA. MHC restriction by MSCs
is controversial. Whereas some human and mouse
studies have reported an absence of MHC restric-
tion [27,31], others have demonstrated preferential
expansion of human umbilical cord blood–derived
CD341 cells cultured on MHC-matched amnion-de-
rived MSCs [40]. Similarly, in studies using B10
congenic strains of mice, hematopoietic stem cell
cobblestone colony formation was superior on MHC-
matchedMSCs comparedwithmismatchedMSCs [41].
Although cell culture supernatants of MSCs con-
tained measurable levels of TGF-b, these levels were
not sufficient to account for immunosuppression,
suggesting the possible involvement of other factors.
Similarly, Rasmusson et al. [30] reported that even
when increasing concentrations of MSCs were added
to an MLR, the TGF-b level in the medium did not
change, consistent with the notion that the immuno-
suppressive effects are not solely because of TGF-b.
Although MSC culture supernatants failed to sup-
press lymphocyte proliferation in the MLRs, they
suppressed the MLRs in a transwell system as effec-
tively as MSCs added directly to the MLRs, indicat-
ing the involvement of inhibitory soluble factors that
required communication between PBMCs and MSCs
to trigger the release of these factors from the MSCs.
The addition of indomethacin, an inhibitor of PGE2
biosynthesis, restored lymphocyte proliferation in thets fromDLA-Identical Donors after 100 cGy TBI andMMF/CsA
MSCs at Days 0 and 35 (MSC)
SCs in Preinjection MLR, %
Day 35
Duration of
Donor Chimerism,
PBMCs, Weeks
Final Status of
Donor Marrow Cells
91.5 11 Rejected
31.7 7 Rejected
70.4 7 Rejected
74.6 9 Rejected
– 12 Rejected
– 10 Rejected
– 3 Rejected
– 3 Rejected
– 10 Rejected
– 10 Rejected
– 9 Rejected
– 11 Rejected
– 3 Rejected
– 9 Rejected
– 9 Rejected
porine; MSCs, mesenchymal stromal cells. Inhibition index refers to the
Figure 6. Duration of engraftment of donor marrow after 100 cGy TBI
and immunosuppression with MMF/CsA and 2 doses of MSCs. Four dogs
received HCT from DLA-identical littermates after 100 cGy TBI. Post-
grafting immunosuppression consisted of 2 injections of MSCs (days
0 and 35) and twice-daily injections of MMF (days 0-28) and CsA (days
21 to 35). Percent donor chimerism was evaluated weekly from the pe-
ripheral blood of the recipients by VNTR-PCR for granulocytes (A) and
lymphocytes (B).
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proliferation and cytokine production [42]. In addi-
tion, the suppression of lymphoproliferation might
have been mediated by release of indoleamine 2,3, di-
oxygenase (IDO) from MSCs [43]. IDO release also
has been shown to be sensitive to inhibitors of pros-
taglandin biosynthesis [44].
Given the reported benefits of MSCs on BM en-
graftment [15,45,46], we investigated the in vivo
immunosuppressive qualities of MSCs in a well-
established model of DLA-identical BM transplanta-
tion. Toward this end, we conditioned recipient dogs
with 100 cGy TBI, which is just below the bar of 200
cGy TBI at which consistent, sustained engraftment
is seen [1]. Extensive immunology studies in dogs not
given BM grafts have shown that although 100 cGy
TBI is immunosuppressive, the suppression is less
profound than that afforded by 200 cGy in almost
all parameters studied [2]. For example, 100 cGy
decreased the lymph node CD3 cell content on day 7
by 50%, compared with 78% with 200 cGy. On the
other hand, MLR responses were absent during the
first 2 weeks and on day 35 after TBI in both dogs
given 100 cGy and those given 200 cGy. Beyond its
immunosuppressive properties, 100 cGy TBI caused
significant BM ablation, resulting in 50%-80%
declines in peripheral blood neutrophil, lymphocyte,and platelet counts [5]. Thus, there should have been
sufficient BM space forMSCs to engraft.We were fur-
ther encouraged to use 100 cGy in our model because
previous studies had shown that inducing host-versus-
graft immune hyporesponsiveness by T cell costimula-
tory blockade in addition to 100 cGy TBI resulted in
extended and stable donor cell engraftment [5,6].
The in vitro functional activity of MSCs was
confirmed in MLR at the time of injection. All 4
dogs engrafted, but eventually rejected their grafts.
The duration of donor engraftment in the
MSC-treated dogs did not differ significantly from
that in 11 historical control dogs not given MSCs.
The complete absence of stable engraftment following
2 injections of BM donor-derived MSCs was unex-
pected but suggests the absence of powerful in vivo im-
munosuppressive effects of these cells in this setting.
Similar results were obtained in a murine parental
into F1 model of GVHD [47]. But, although potent in
vitro immunosuppressive properties of MSCs derived
from BM, placenta or umbilical cord tissues were dem-
onstrated, multiple injections of the maximum
allowable numbers of MSCs failed to prevent
GVHD in BM recipients. Localized injection of
MSCs under the kidney capsule did, however, result
in ectopic bone production, suggesting maintenance
of one in vivo function of MSCs.
Conversely, other studies in mice [48] and rats [49]
demonstrated that repeated i.v. injections of recipient
adipocyte-derived MSCs could reverse mild GVHD.
Collectively, our results and results obtained from pre-
vious models suggest that the correct paradigm for in
vivo MSC immunosuppression (perhaps by route of
injection or cell number) has yet to be fully defined. Al-
though the MSC doses in the present study (mean,
1.2  106 cells/kg) were consistent with those used by
others [15-17,45,46,50,51] the possibility that higher
doses or more frequent administration of MSCs
could improve the success in our model cannot be
ruled out.
In conclusion, our findings indicate that canine
MSCs have the same cytological features and in vitro
immunosuppressive and immunomodulatory effects
as reported for humans and mice. However, MSCs
failed to promote sustained hematopoietic engraft-
ment in dogs given conditioning with low-dose TBI.ACKNOWLEDGMENTS
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